about
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyWilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyFavorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaRUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.GAS6 expression identifies high-risk adult AML patients: potential implications for therapyIDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaFLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyPrognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B studyComparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.MicroRNA expression in cytogenetically normal acute myeloid leukemia.Pluripotent stem cell miRNAs and metastasis in invasive breast cancer.Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics.Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapyUp-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemiamiR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemiaLenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemiainv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene scoreSPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
P50
Q24643738-00E379AD-7FE0-4FC8-A29E-F86987AF355FQ27851436-7017345D-EE9B-4037-BCE1-81D39D470350Q27851545-1B769B56-A358-44C4-9FE0-DE35C2AAF645Q27851621-5D4C4F65-6DB5-4687-97D6-D024E5D0C613Q27851679-76288461-F161-4F95-9EE5-6EB421D80646Q27851713-D8DB8942-1C00-4659-A18E-301E58275FB9Q27851839-5904A040-1AB3-4109-AFC3-54BB0319FB1CQ33717707-E7115D0E-C225-4CA0-9B3A-0F77B0FE1D50Q33897586-03D2232B-FF4E-439C-BD5F-4C49F83A39E5Q34048276-4C0969EE-861F-4065-97BE-2E49D6CEF837Q34052614-47CC6341-5462-479C-93DE-C3ADC0ECFE95Q34056156-DC35DF2A-F0D8-45E5-81FE-F84507C340FBQ34069811-09AF043E-6C18-47C2-8045-C2358E40D820Q34119417-877E27AF-CC9C-4501-8E7A-B31939ECC90EQ34124919-4A8D67EE-3030-4938-887F-B3930C568B87Q34197535-4D79256A-D52D-43A9-8061-BF9AAFF3D4C5Q34310561-3304E893-9B94-4E38-8C29-6E70B42F1DCCQ34477821-99AE8FC4-3463-4682-8BDB-47A72158E839Q34541748-43DF1DF4-BE09-469B-8D67-B026AC6ED539Q34593276-02C22E2A-CA6E-4EC1-9EB3-EB4BCE817DE5Q34630588-844507E3-48D2-4103-BEA3-18F531568E89Q34775265-8E11DD14-7CB4-4FE2-8BCE-FA56AA1B0CD4Q35102562-D9A71057-9EFA-484D-BFF0-AF33D896B0C0Q35265946-DA0393D6-ED56-4323-AE1C-615C1836F98EQ35686077-26B223F2-EDCE-4227-BACC-091202BFE242Q35794120-6716A9DE-61E8-48FE-B4EF-C1B2D4C4E502Q35847845-486CE468-5A36-4EAF-9BF5-21BBCF1647EEQ35849255-FD938438-F596-4A8B-8E0C-7A6322E9DAC3Q35922032-68010F96-E012-41C5-A522-C69BE0FBFC48Q36100455-19D831BD-27B7-459B-8A0F-E2A8A0F28D43Q36512601-7E8BC2E8-6E47-4109-9094-3440237027B9Q36529502-D7678C35-B92F-44BE-BD2A-5B4049A7B689Q36843784-22AA5EC2-94BA-4572-8172-2DFFD2CD6055Q37119445-25990C84-AA3C-455C-89FD-364D9AF68E71Q37570427-B49DDA1B-580E-4CB5-BD99-A06F5E3EF883Q37679943-7FF4C196-ABA5-456E-87B2-06224D195A5DQ43065871-16C2C09D-6A0D-4117-BEA3-8AFF172367E5Q46091563-FDC33810-3C86-4E32-8DB3-809E08BF657FQ46658495-C74149F5-024A-4F84-BB34-4A1B504D3B82Q50771779-B84AB7CC-A168-4BDA-BC89-0395683186A0
P50
name
Kati Maharry
@ast
Kati Maharry
@en
Kati Maharry
@nl
type
label
Kati Maharry
@ast
Kati Maharry
@en
Kati Maharry
@nl
prefLabel
Kati Maharry
@ast
Kati Maharry
@en
Kati Maharry
@nl